Accelerating Approval of Botanical Medicine to Transform
and Drive Explosive Growth in the Global Healthcare Industry
Although the US spends twice as much on healthcare than other high-income nations, the US remains the sickest first world country on earth. Compared to other developed countries, the US has the shortest life expectancy and highest infant mortality rate. Plagued with chronic degenerative diseases, the vast majority of American patients are treated with expensive drugs that only mask symptoms and are filled with side effects. These same drugs have become the standard of care in many countries all over the world. When patients do not recover from disease, most end up in hospitals sooner or later. Endless patient hospitalizations are bankrupting our healthcare systems.
Many companies produce natural botanical therapies that are more effective, safer and cheaper than mainstream drugs. Botanical therapies treat the root cause of disease and the best botanicals can reverse acute and chronic diseases with sustained results and no side effects. In 2004 the FDA developed guidelines for botanical therapies to become approved botanical drugs. Just like conventional drugs, botanical drugs are prescribed to patients to treat disease and have insurance coverage. Unfortunately patients never find out about these treatments because botanical companies are neglected by centralized VC funds and do not have equal access to capital for clinical trials.
In December 2016 the FDA relaxed botanical drug approval guidelines to catch up with global standards, creating a huge opportunity for the worldwide expansion of botanical medicine. The US botanical drug industry is an open and untapped $153 billion market. PhytaZenica is a healthcare tech company that provides a global, decentralized digital fundraising platform and key resources to accelerate development and approval of botanical medicine. Our platform raises funding from millions of investors all over the world instantly for botanical clinical trials, approval and commercialization, as well as provide clinical trial design and supply chain validation for botanicals. Using blockchain technology and our digital currency phyta, our platform operates at record-breaking speeds with
1 second transactions and provides high scalability at 10,000 transactions per second (TPS).
We are driving the expansion of botanical medicine to transform global healthcare. PhytaZenica is:
Our Business Model
Jennifer M. Wong
Co-Founder & Chief Executive Officer
Jennifer created the original vision for PhytaZenica and is leading the strategic and overall execution of our venture. She has over 10 years of experience in business strategy, market research, competitive intelligence, marketing and sales for the healthcare and biopharmaceutical industries. Jennifer has worked closely with top global biotech companies, as well as botanical companies in the US. Jennifer holds a bachelor’s degree in Integrative Biology from UC Berkeley.
Alex Huang, MS
Co-Founder & Chief Scientific Officer
Alex is the founder and CEO of US botanical companies Quellthera and LiveLeaf. He is an entrepreneur with 35 years of experience in biotech, medical devices and tech. Alex created a model to transform active botanical compounds into targeted botanical drugs. His products have patent protection and have gone through human clinical trials with hundreds of patients all over the world. Alex holds a BS in mechanical engineering, a BS in electrical engineering, and an MS in product design from Stanford University.
Chief Technology Officer & Investor
Andreas is a tech entrepreneur and investor specializing in blockchain, cryptocurrency, web platform and software creation, and digital marketing. He is the founder of Dolla, a secure, fast and cost-effective cryptocurrency. Andreas is skilled in business creation, promotion, operations and expansion. Leading a team of world-class developers, Andreas is designing and building PhytaZenica's blockchain platform, which will operate at record-breaking speeds with 1 second transactions and provide high scalability at 10,000 TPS.
PB Stanton, ESQ.
Chief Legal Officer
PB is a US-based attorney fluent in cryptocurrency, blockchain, securities and banking law compliance. He is a trusted ICO & STO adviser who leads or guides all phases from project ideation, tokenomics and whitepaper creation, to full ICO & STO launches. PB's law career began in the US Marine Corps as a JAG Officer stationed at Camp Pendleton, CA. He spent 25+ years providing asset protection, estate planning & tax planning services to affluent individuals and families, prestigious institutions and other high-value clients.
Dr. Shaw Chen, MD/PhD
Botanical Drug Expert
Jie Hou, MS
Blockchain & Fintech Strategist
Bas Geelen, MS
Strategy & Branding Consultant